These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

757 related articles for article (PubMed ID: 31374358)

  • 1. How to Treat Patients with Chronic Spontaneous Urticaria with Omalizumab: Questions and Answers.
    Türk M; Carneiro-Leão L; Kolkhir P; Bonnekoh H; Buttgereit T; Maurer M
    J Allergy Clin Immunol Pract; 2020 Jan; 8(1):113-124. PubMed ID: 31374358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Omalizumab Updosing in Chronic Spontaneous Urticaria: an Overview of Real-World Evidence.
    Metz M; Vadasz Z; Kocatürk E; Giménez-Arnau AM
    Clin Rev Allergy Immunol; 2020 Aug; 59(1):38-45. PubMed ID: 32418171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of omalizumab treatment for pediatric chronic spontaneous urticaria: A multi-center retrospective case series.
    Ari A; Levy Y; Segal N; Maoz-Segal R; Benor S; Broides A; Horev A; Epstein-Rigbi N; Agmon-Levin N; Marcus N
    Pediatr Dermatol; 2020 Nov; 37(6):1051-1054. PubMed ID: 32951239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of chronic spontaneous urticaria with an inadequate response to H1-antihistamines: an expert opinion.
    Vestergaard C; Toubi E; Maurer M; Triggiani M; Ballmer-Weber B; Marsland A; Ferrer M; Knulst A; Giménez-Arnau A
    Eur J Dermatol; 2017 Feb; 27(1):10-19. PubMed ID: 27882879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atopy and Response to Omalizumab Treatment in Chronic Spontaneous Urticaria.
    Costa C; Esteves Caldeira L; Paulino M; Santos DF; Silva SL
    Int Arch Allergy Immunol; 2024; 185(3):260-266. PubMed ID: 38113870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Omalizumab versus cyclosporin-A for the treatment of chronic spontaneous urticaria: can we define better-responding endotypes?
    Kocatürk E; Başkan EB; Küçük ÖS; Özdemir M; Örnek S; Can PK; Haşal E; Engin B; Atakan N; Alpsoy E
    An Bras Dermatol; 2022; 97(5):592-600. PubMed ID: 35853771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of omalizumab on angioedema in H1 -antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial.
    Staubach P; Metz M; Chapman-Rothe N; Sieder C; Bräutigam M; Canvin J; Maurer M
    Allergy; 2016 Aug; 71(8):1135-44. PubMed ID: 27010957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the Efficacy and Recurrence of Omalizumab Use in the Treatment of Chronic Spontaneous Urticaria and Chronic Inducible Urticaria.
    ; Yu R; Qian W; Zheng Q; Xiong J; Chen S; Chen A; Chen J; Fang S; Huang K; Cai T
    Int Arch Allergy Immunol; 2023; 184(7):643-655. PubMed ID: 36996780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patients With Chronic Spontaneous Urticaria Who Have Wheals, Angioedema, or Both, Differ Demographically, Clinically, and in Response to Treatment-Results From CURE.
    Buttgereit T; Vera C; Aulenbacher F; Church MK; Hawro T; Asero R; Bauer A; Bizjak M; Bouillet L; Dissemond J; Fomina D; Giménez-Arnau AM; Grattan C; Gregoriou S; Kulthanan K; Kasperska-Zajac A; Kocatürk E; Makris M; Kolkhir P; Weller K; Magerl M; Maurer M
    J Allergy Clin Immunol Pract; 2023 Nov; 11(11):3515-3525.e4. PubMed ID: 37604426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biologics for the Use in Chronic Spontaneous Urticaria: When and Which.
    Maurer M; Khan DA; Elieh Ali Komi D; Kaplan AP
    J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1067-1078. PubMed ID: 33685605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Omalizumab for treating chronic spontaneous urticaria: an expert review on efficacy and safety.
    Giménez-Arnau AM
    Expert Opin Biol Ther; 2017 Mar; 17(3):375-385. PubMed ID: 28125304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Omalizumab in the Treatment of Chronic Urticaria: The Effect of Drug Co-Administration and Co-Morbidities.
    Tagka A; Lambrou GI; Nicolaidou E; Nakou E; Makris M; Stratigos A; Katsarou A
    Antiinflamm Antiallergy Agents Med Chem; 2021; 20(1):39-50. PubMed ID: 32013838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effective treatment of different phenotypes of chronic urticaria with omalizumab: Case reports and review of literature.
    Kasperska-Zajac A; Jarząb J; Żerdzińska A; Bąk K; Grzanka A
    Int J Immunopathol Pharmacol; 2016 Jun; 29(2):320-8. PubMed ID: 26729404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of omalizumab in adolescent and adult patients with chronic idiopathic/spontaneous urticaria: a systematic review of 'real-world' evidence.
    Bernstein JA; Kavati A; Tharp MD; Ortiz B; MacDonald K; Denhaerynck K; Abraham I
    Expert Opin Biol Ther; 2018 Apr; 18(4):425-448. PubMed ID: 29431518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Classification, Pathogenesis, Diagnostic Workup, and Management of Urticaria: An Update.
    Maurer M; Zuberbier T; Metz M
    Handb Exp Pharmacol; 2022; 268():117-133. PubMed ID: 34247278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing Value in the Evaluation of Chronic Spontaneous Urticaria: A Cost-Effectiveness Analysis.
    Shaker M; Oppenheimer J; Wallace D; Lang DM; Rambasek T; Dykewicz M; Greenhawt M
    J Allergy Clin Immunol Pract; 2020; 8(7):2360-2369.e1. PubMed ID: 31751758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Omalizumab in Chronic Spontaneous Urticaria (CSU): Real-Life Experience in Dose/Interval Adjustments and Treatment Discontinuation.
    Brás R; Costa C; Limão R; Caldeira LE; Paulino M; Pedro E
    J Allergy Clin Immunol Pract; 2023 Aug; 11(8):2392-2402. PubMed ID: 36720390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stepping Down Treatment in Chronic Spontaneous Urticaria: What We Know and What We Don't Know.
    Terhorst-Molawi D; Fox L; Siebenhaar F; Metz M; Maurer M
    Am J Clin Dermatol; 2023 May; 24(3):397-404. PubMed ID: 36810982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The future of targeted therapy in chronic spontaneous urticaria.
    Min TK; Saini SS
    Ann Allergy Asthma Immunol; 2024 Oct; 133(4):367-373. PubMed ID: 38885835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-TPO IgG/Total IgE Ratio: Biomarker for Omalizumab Response Prediction in Chronic Spontaneous Urticaria.
    Brás R; Esteves Caldeira L; Bernardino A; Costa C
    Int Arch Allergy Immunol; 2023; 184(9):866-869. PubMed ID: 37557083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.